MiMedx Group, Inc (NASDAQ:MDXG) Stock Rated “Moderate Buy” by Wall Street Brokerages

MiMedx Group, Inc (NASDAQ:MDXG) has received an average rating of “Moderate Buy” from the seven brokerages that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $8.57.

MDXG has been the topic of several recent research reports. Raymond James Financial set a $8.00 price objective on MiMedx Group in a research note on Monday, August 17th. Seaport Research Partners downgraded shares of MiMedx Group to a “neutral” rating in a research report on Monday, August 17th. Cantor Fitzgerald restated an “overweight” rating on shares of MiMedx Group in a research note on Tuesday, September 15th. Weiss Ratings upgraded shares of MiMedx Group from a “sell (d)” rating to a “sell (d+)” rating in a research note on Thursday, August 27th. Finally, Wall Street Zen raised shares of MiMedx Group from a “sell” rating to a “hold” rating in a report on Saturday, August 29th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. GAMMA Investing LLC increased its stake in MiMedx Group by 2,422.5% during the 3rd quarter. GAMMA Investing LLC now owns 7,719 shares of the company’s stock valued at $36,000 after purchasing an additional 7,413 shares in the last quarter. Sunbelt Securities Inc. acquired a new stake in shares of MiMedx Group during the first quarter worth $42,000. E Fund Management Co. Ltd. acquired a new stake in shares of MiMedx Group during the second quarter worth $45,000. Syon Capital LLC acquired a new stake in shares of MiMedx Group during the second quarter worth $45,000. Finally, Legal & General Group Plc purchased a new stake in shares of MiMedx Group during the second quarter valued at $45,000. 79.15% of the stock is owned by hedge funds and other institutional investors.

MiMedx Group Price Performance

MDXG opened at $4.83 on Tuesday. The company has a current ratio of 5.33, a quick ratio of 4.79 and a debt-to-equity ratio of 0.07. The company has a market cap of $704.02 million, a price-to-earnings ratio of 120.78 and a beta of 1.18. The stock has a fifty day simple moving average of $4.52 and a two-hundred day simple moving average of $4.06. MiMedx Group has a 12-month low of $3.03 and a 12-month high of $7.97.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.05) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.05). The business had revenue of $64.36 million during the quarter, compared to analyst estimates of $63.46 million. MiMedx Group had a net margin of 1.76% and a return on equity of 12.09%. Research analysts predict that MiMedx Group will post -0.10 earnings per share for the current fiscal year.

MiMedx Group Company Profile

MiMedx Group, Inc is a regenerative healthcare company that develops, manufactures and markets human placental tissue allografts and related biomaterial products. Its products are derived from donated human placental tissue and are processed for use in healthcare settings, including wound care, surgery and orthopedic applications.

The company’s portfolio includes tissue allografts such as EPIFIX, EPIEFFECT, GRAFIX and AMNIOFIX. These products are designed to support the management of chronic and acute wounds, surgical reconstruction and other clinical procedures.